Transparency, a harm reduction organization specializing in at-home drug testing kits, has announced its official launch as the parent organization of the Bunk Police.
The growing opioid crisis in the US has been exacerbated by various systems and biases, preventing individuals from accessing critical treatments like methadone and buprenorphine.
In an inspiring conversation with Liza Laws, Dr. Michael Giles, MD, and chief executive officer of Sonara Health, shares the innovative journey of creating a platform to enhance the accessibility of methadone treatment for opioid use disorder patients.
Access to opioids such as fentanyl can lead to abuse but now two companies have signed an agreement to reduce the abuse potential while making sure they are still accessible to those who need them.
The naloxone hydrochloride nasal spray will be made available over-the-counter, therefore not requiring a prescription, in an effort to reduce deaths from opioid abuse.
Emergent’s application for its Narcan product to be sold OTC for the treatment of opioid overdose has been accepted by the US FDA and provided priority review.
CVS Health and Walgreens announce that they will settle all opioid claims against them by US states, while it is reported that Walmart will do the same.
The agency has given the go-ahead on an IND application for a study evaluating Ananda Scientific’s Nantheia ATL5, a candidate for treating opioid use disorder.
As part of its efforts to reach a global settlement to resolve opioid claims, Mallinckrodt will file for Chapter 11 bankruptcy for its specialty generics subsidiary.
Johnson & Johnson reaches $20m settlement with two US counties on lawsuits regarding the opioid crisis, exits the upcoming federal trial involving several drug manufacturers.
US FDA follows up the first generic approval of naloxone nasal spray by encouraging companies to apply with generic applications amid the North American opioid crisis.
Purdue reaches agreement to settle opioid litigation it is facing in the US by pursuing bankruptcy and providing a suggested $10bn towards the opioid crisis.
Mallinckrodt announces a settlement agreement on a lawsuit included in the first federal trial over the opioid crisis, shortly after reaching a deal on a previous investigation.
J&J is ordered to pay $572m to the state of Oklahoma, after a court judgement found against the pharmaceutical company for its role in the opioid crisis.
Researchers discover scorpion toxin that triggers pain through a previously unknown pathway, potentially opening up new avenues of investigation for treating chronic pain.
July has seen a number of actions taken by regulators to manage the supply of medicine, including a crackdown on CBD manufacturers and repackers of opioid medication.
Insys announces that it will file for Chapter 11 bankruptcy following the settlement of a legal case regarding its sales tactics for its opioid-based pain killer.
WCG acquires Analgesic Solutions for advisement on protocol design and the development of clinical trials in which pain is an indicator of an underlying condition.
US FTC rules that Endo used its dominant position in the market to delay competition from Impax with an illegal pay-for-delay deal for its Opana ER product.
The FDA issued a warning letter to McKesson for violations concerning a possible distribution of illegitimate opioid products while calling for action in securing the supply chain from illegitimate medications, especially opioids.
Purdue announced that it has entered into a partnership deal with Alivio to develop a non-opioid painkiller for the treatment of cystitis and bladder pain syndrome.
The US Court of Appeals for the Federal Circuit removed the injunction against Dr. Reddy’s, which prevented the company from selling its Suboxone generic.
The US opioid crisis has been driven by early use in standard care, says Opiant director Gabrielle Silver, who urges pharma to ‘think differently’ to enable change.
President Donald Trump signed the SUPPORT Act granting the FDA additional authority to combat the opioid epidemic, but a pain management CRO argues that opioid addiction isn't the only crisis.
President Donald Trump signed the SUPPORT act granting the FDA additional authority to combat the opioid epidemic, but a pain management CRO argues that opioid addiction isn’t the only crisis.